Point-of-care diagnostics for invasive aspergillosis: nearing the finish line.

Published in: Expert review of molecular diagnostics (2020)

Several new diagnostic tests for IA - including point-of-care tests - are now available to complement conventional galactomannan (GM) testing. In particular, the Aspergillus-specific Lateral Flow Device (LFD) test and the sōna Aspergillus GM Lateral Flow Assay (LFA) are promising for the diagnosis of IA in patients with hematologic malignancy, although further evaluation in the non-hematology setting is needed. In addition, a true point-of-care test, particularly for easily obtained specimens like serum or urine that can be done at the bedside or in the Clinic in a matter of minutes is needed, such as the lateral flow dipstick test, which is under current evaluation. Lastly, improved diagnostic algorithms to diagnose IA in non-neutropenic patients is needed.

Keyphrases

end stage renal disease
ejection fraction
chronic kidney disease
newly diagnosed
machine learning
primary care
peritoneal dialysis
high throughput
deep learning
cell wall
single cell
patient reported